Inside SYNG Pharma’s decade-long mission as it prepares to launch endometriosis test EndoID
Commercial rollout begins in India in early 2026
For the past decade, Canadian researcher-turned-founder Vinay Singh has been building SYNG Pharma, a startup developing a simple blood test for endometriosis called EndoID.
When few investors would back the idea, his sheer belief in the idea and its potential led him to keep it alive himself - funding experiments from his own pocket, borrowing lab space, and calling in favours from former colleagues.
While Vinay was fortunate to be in a position to bootstrap, he could also see what investors were missing:
“I would walk into investor rooms full of men who had never even heard of endometriosis,” Singh recalls.
“I’ve met investors who will say, I have daughters with endometriosis. Good luck to you. But I still can’t invest.”
A decade on and SYNG Pharma is at a turning point.
In the last three months alone, its diagnostic tool, EndoID has secured regulatory approval in India, with a commercial rollout planned for early 2026.
Clinical trials are running in Canada, and the company is planning to expand to the UK, France and the US through new partnerships.
EndoID detects endometriosis
EndoID is a dual-biomarker diagnostic that analyses either serum (a small blood draw) or menstrual blood to detect molecular signals of endometriosis. It’s designed as a first-line screen - quick, affordable, and non-invasive - that anyone can order online and do at home but which could drastically shorten the average eight-year wait for diagnosis.
The test runs on standard ELISA lab technology and measures two key proteins, SNCG and BCL6, which together provide a distinctive fingerprint of the condition. Results can be ready in just a few hours.
Vinay says the goal isn’t to replace physicians but to help with triaging patients by providing an early ‘yes’ or ‘no’ tool that can help decide what further care is needed.
“For a 14, 15-year-old young girl who would not go for invasive procedure… we wanted to have an accessible and affordable solution,” Vinay says.
Although the first generation of EndoID will rely on serum samples, Vinay sees menstrual blood as the next frontier because of its additional sensitivity and special insight into uterine health.
His team has already developed a prototype for a lateral-flow device - similar to a pregnancy test - that could one day detect endometriosis from a single drop of blood.
Market by market
First up for the serum sample test is India where SYNG Pharma is partnering with major pathology chains, IVF clinics and gynecology networks for the 2026 launch - a milestone that Vinay says “makes it real.”
Rather than launch first in Canada or the U.S, Vinay chose India because of lower costs, hospital openness to pilot new ideas and the potential for adoption to happen the fastest.
“In India, everything was available to me at one place and we could do it at one tenth of the cost.”
The company is also pursuing CE marking in Europe, supported by new clinical collaborations - and sees the UK as its preferred next step. Through participation in the Canadian Technology Accelerator (CTA) programme, SYNG Pharma will be visitng the UK to meet clinical key opinion leaders and strategic partners, exploring trials and early adoption opportunities.
And, as the team prepares to expand, Singh is keenly aware that medical innovation also means cultural translation. They’ve already found that each country has its own comfort level and its own language around menstruation. Vinay uses the example of menstrual cups for blood collection which are popular in some countries but less so in others like India.
Completing a deeply personal mission
Like many founders, Vinay has a personal mission behind this work too and so he understands the individual impact of EndoID.
“Why it was relevant to me is because my wife had PCOS. People very close to me had endometriosis. I knew the suffering and pain. My very good friend, my PhD colleague, she would take three days off to not be able to work. And I used to help her in those days.
“So it was deeply personal and close to me.”
SYNG Pharma is one of nine startups selected for the 2025 Canadian Technology Accelerator (CTA) FemTech program organised by the High Commission Canada in the UK and the Embassy in Paris, France. This free program provides access to advisors, a peer network, regular masterclasses and a dedicated visit to the UK and France to support founders with understanding the market landscape and potential opportunities. This article is part of a partnership with the High Commission Canada.